By Abhishek Vishnoi
MUMBAI (Reuters) - The BSE Sensex and Nifty rose on Tuesday to their highest close in more than a month, with drugmakers getting a shot in the arm after Ranbaxy Laboratories Ltd reported its first profit in six quarters.
Lenders also extended recent gains on rising expectations the Reserve Bank of India would cut rates earlier than expected next year as slumping crude prices are expected to ease inflationary pressures.
Hopes for a loosening of monetary policy were also spurred after Finance Minister Arun Jaitley said he favoured a cut in interest rates, during an interview with a newspaper last week.
Also helping Tuesday's gains were higher global stocks ahead of the U.S. Federal Reserve's two-day meet, where it is expected to reinforce that a softly-softly approach would be taken to raising rates.
"Interest rates, inflation, reform cycle... everything is in India's favour but it will come down to the Fed's language on rates for the near-term direction," said Nirakar Pradhan, chief investment officer at Future Generali India Life Insurance.
The Sensex rose 0.48 percent, or 127.92 points, to end at 26,880.82.
The broader Nifty gained 0.45 percent, or 35.90 points, to end at 8,027.60, above the psychologically important 8,000 level.
Both indexes rose for a sixth day in seven and marked their highest close since Sept. 22.
Ranbaxy surged 5.9 percent and was among the leading gainers on the index after swinging to a net profit in the July-September quarter, helped by the exclusive U.S. launch of a generic version of Novartis AG's blood pressure pill Diovan.
Sun Pharmaceutical Industries , which is in the process of acquiring Ranbaxy, rose 4.2 percent.
Cipla rose 2.9 percent, while Aurobindo Pharma finished higher 3 percent.
Lenders rose amid continued hopes of a rate cut and reforms in the sector. State Bank of India closed up 2.3 percent, while ICICI Bank Ltd ended higher 1.8 percent.
Ruchi Soya Industries rose 1.9 percent. India is considering raising import taxes on crude and refined vegetable oils to protect local farmers and the refining industry, two government sources said.
However, Jubilant Foodworks fell 2.2 percent ahead of its September-quarter results on Thursday. Traders worried the company's same-store sales might be weak given increasing competition.
(Editing by Prateek Chatterjee)
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
